ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
The Lancet Respiratory Medicine
◽
10.1016/s2213-2600(19)30262-0
◽
2020
◽
Vol 8
(1)
◽
pp. 25-33
◽
Cited By ~ 26
Author(s):
Luca Richeldi
◽
Evans R Fernández Pérez
◽
Ulrich Costabel
◽
Carlo Albera
◽
David J Lederer
◽
...
Keyword(s):
Growth Factor
◽
Idiopathic Pulmonary Fibrosis
◽
Connective Tissue
◽
Controlled Trial
◽
Tissue Growth
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Factor Therapy
◽
Growth Factor Therapy
Download Full-text
Related Documents
Cited By
References
Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial
SSRN Electronic Journal
◽
10.2139/ssrn.3379814
◽
2019
◽
Author(s):
Luca Richeldi
◽
Evans R. Fernández Pérez
◽
Ulrich Costabel
◽
Carlo Albera
◽
David J. Lederer
◽
...
Keyword(s):
Growth Factor
◽
Idiopathic Pulmonary Fibrosis
◽
Connective Tissue
◽
Pulmonary Fibrosis
◽
Controlled Trial
◽
Tissue Growth
◽
Double Blind
◽
Double Blind Placebo
◽
Factor Therapy
◽
Growth Factor Therapy
Download Full-text
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Case Medical Research
◽
10.31525/ct1-nct03926117
◽
2019
◽
Author(s):
Keyword(s):
Renal Disease
◽
Chronic Renal Disease
◽
Controlled Trial
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: A phase 2, randomised, double-blind, placebo controlled trial
Maturitas
◽
10.1016/j.maturitas.2017.03.319
◽
2017
◽
Vol 100
◽
pp. 142-143
Author(s):
Julia Prague
◽
Rachel Roberts
◽
Alexander Comninos
◽
Sophie Clarke
◽
Channa Jayasena
◽
...
Keyword(s):
Controlled Trial
◽
Hot Flushes
◽
Phase 2
◽
Double Blind
◽
Receptor Antagonism
◽
Double Blind Placebo
◽
Novel Treatment
◽
Neurokinin 3 Receptor
Download Full-text
P1-067: AMBROXOL AS PHARMACOLOGICAL CHAPERONE TARGETING GBA1 AS A DISEASE MODIFYING TREATMENT FOR PARKINSON'S DISEASE DEMENTIA: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Alzheimer s & Dementia
◽
10.1016/j.jalz.2018.06.069
◽
2006
◽
Vol 14
(7S_Part_5)
◽
pp. P296-P296
Author(s):
Stephen H. Pasternak
◽
Carolina Silveira
◽
Zhonghan Li
◽
Robert Bartha
◽
Michael Borrie
◽
...
Keyword(s):
Parkinson’S Disease
◽
Parkinson's Disease
◽
Controlled Trial
◽
Phase 2
◽
Parkinson’S Disease Dementia
◽
Double Blind
◽
Pharmacological Chaperone
◽
Double Blind Placebo
◽
Disease Modifying
◽
Disease Modifying Treatment
Download Full-text
OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial
Retrovirology
◽
10.1186/1742-4690-6-s3-o25
◽
2009
◽
Vol 6
(S3)
◽
Cited By ~ 1
Author(s):
D Salmon-Céron
◽
C Durier
◽
C Desaint
◽
Cuzin
◽
M Surenaud
◽
...
Keyword(s):
Controlled Trial
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Hiv 1
Download Full-text
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
The Lancet
◽
10.1016/s0140-6736(19)32135-x
◽
2019
◽
Vol 394
(10208)
◽
pp. 1540-1550
◽
Cited By ~ 44
Author(s):
Rajiv Agarwal
◽
Patrick Rossignol
◽
Alain Romero
◽
Dahlia Garza
◽
Martha R Mayo
◽
...
Keyword(s):
Chronic Kidney Disease
◽
Kidney Disease
◽
Resistant Hypertension
◽
Controlled Trial
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
The Lancet Neurology
◽
10.1016/s1474-4422(11)70299-x
◽
2012
◽
Vol 11
(2)
◽
pp. 131-139
◽
Cited By ~ 54
Author(s):
David H Miller
◽
Thomas Weber
◽
Richard Grove
◽
Claire Wardell
◽
Joseph Horrigan
◽
...
Keyword(s):
Multiple Sclerosis
◽
Controlled Trial
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Relapsing Remitting
◽
Remitting Multiple Sclerosis
◽
Relapsing Remitting Multiple Sclerosis
Download Full-text
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Respiratory Medicine
◽
10.1016/s2213-2600(16)30044-3
◽
2016
◽
Vol 4
(6)
◽
pp. 445-453
◽
Cited By ~ 67
Author(s):
Jürgen Behr
◽
Elisabeth Bendstrup
◽
Bruno Crestani
◽
Andreas Günther
◽
Horst Olschewski
◽
...
Keyword(s):
Idiopathic Pulmonary Fibrosis
◽
Pulmonary Fibrosis
◽
Combination Therapy
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Phase 2 Trial
Download Full-text
Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases
10.1158/1538-7445.sabcs15-ot2-01-05
◽
2016
◽
Author(s):
RE Coleman
◽
L Huang
◽
O Petrenciuc
◽
P Zaccarini
◽
HS Rugo
Keyword(s):
Controlled Trial
◽
Growth Factor Receptor
◽
Phase 2
◽
Breast Cancer Patients
◽
Double Blind
◽
Double Blind Placebo
◽
Hormone Receptor Positive
◽
Radium 223
◽
Epidermal Growth
◽
Positive Breast Cancer
Download Full-text
“Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction”: study protocol for a randomized controlled trial
Trials
◽
10.1186/s13063-020-04652-0
◽
2020
◽
Vol 21
(1)
◽
Author(s):
Dirk von Lewinski
◽
◽
Joseph B. Selvanayagam
◽
Richard A. Schatz
◽
Bernd Jilma
◽
...
Keyword(s):
Myocardial Infarction
◽
Randomized Controlled Trial
◽
Controlled Trial
◽
Efficacy Study
◽
Phase 2
◽
Early Recovery
◽
Double Blind
◽
Safety And Efficacy
◽
Double Blind Placebo
◽
Randomized Controlled
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close